In patients with CKD anemia not requiring dialysis, Roxadustat elevates Hb levels in a dose-dependent manner, significantly decreases ferritin levels, and briefly increases endogenous EPO levels within or near the physiological range, compared to placebo at high doses. The gene discussed is EPO; the disease is anemia.